Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.

Marcelo Kremenchutzky,Paul O'Connor,Reinhard Hohlfeld,Lixin Zhang-Auberson,Philipp von Rosenstiel,Xiangyi Meng,Augusto Grinspan,Ron Hashmonay,Ludwig Kappos

Multiple Sclerosis and Related Disorders（2014）

引用 11|浏览11

暂无评分

摘要

•Fingolimod reduced the annualized relapse rate (ARR) vs placebo after interferon beta or glatiramer acetate therapy.•Fingolimod reduced ARR after lack of efficacy of prior disease-modifying therapy.•Fingolimod reduced ARR in treatment-naïve patients and patients on DMT >1–3 years.

查看译文

关键词

Disease-modifying therapy,Fingolimod,Multiple sclerosis,Sphingosine 1-phosphate receptor modulator,Treatment history,Relapse rate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要